You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2024

NIFEDIPINE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Nifedipine, and what generic alternatives are available?

Nifedipine is a drug marketed by Acella, Actavis Elizabeth, Chase Labs Nj, Heritage Pharma, Leading, Teva, Alembic, Alkem Labs Ltd, Aurobindo Pharma, Aurobindo Pharma Usa, Elite Pharm Solution, Martec Usa Llc, Mylan, Novast Labs, Osmotica Pharm Us, Par Pharm, Rising, Spil, Twi Pharms, Valeant Pharms North, Vitruvias, and Zydus Pharms. and is included in thirty NDAs.

The generic ingredient in NIFEDIPINE is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the nifedipine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nifedipine

A generic version of NIFEDIPINE was approved as nifedipine by ACTAVIS ELIZABETH on September 20th, 1990.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for NIFEDIPINE?
  • What are the global sales for NIFEDIPINE?
  • What is Average Wholesale Price for NIFEDIPINE?
Drug patent expirations by year for NIFEDIPINE
Drug Prices for NIFEDIPINE

See drug prices for NIFEDIPINE

Drug Sales Revenue Trends for NIFEDIPINE

See drug sales revenues for NIFEDIPINE

Recent Clinical Trials for NIFEDIPINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Queen Mary University of LondonN/A
Medical College of WisconsinPhase 3
Shaheed Zulfiqar Ali Bhutto Medical UniversityN/A

See all NIFEDIPINE clinical trials

Pharmacology for NIFEDIPINE
Medical Subject Heading (MeSH) Categories for NIFEDIPINE

US Patents and Regulatory Information for NIFEDIPINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rising NIFEDIPINE nifedipine TABLET, EXTENDED RELEASE;ORAL 201071-002 Dec 3, 2010 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Osmotica Pharm Us NIFEDIPINE nifedipine TABLET, EXTENDED RELEASE;ORAL 077127-001 Nov 21, 2005 AB2 RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Twi Pharms NIFEDIPINE nifedipine TABLET, EXTENDED RELEASE;ORAL 203126-003 Apr 3, 2014 AB2 RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Pharms NIFEDIPINE nifedipine TABLET, EXTENDED RELEASE;ORAL 210184-002 Jun 29, 2018 AB1 RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Spil NIFEDIPINE nifedipine TABLET, EXTENDED RELEASE;ORAL 210838-002 Apr 16, 2019 AB2 RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.